Brief: Agomab Reports Positive Topline Data From Stenova Open-Label Extension Study Of Ontunisertib In Fibrostenosing Crohn's Disease
01/10/2026 11:35
BRIEF-Agomab Reports Positive Topline Data From Stenova Open-Label Extension Study Of Ontunisertib In Fibrostenosing Crohn's Disease Oct 1 (Reuters) - Agomab Therapeutics NV AGMB.O:
AGOMAB REPORTS POSITIVE TOPLINE DATA FROM STENOVA OPEN-LABEL EXTENSION STUDY OF ONTUNISERTIB IN FIBROSTENOSING CROHN'S DISEASE
AGOMAB THERAPEUTICS NV - FAVORABLE SAFETY AND TOLERABILITY PROFILE MAINTAINED THROUGH 60 WEEKS OF ONTUNISERTIB TREATMENT IN FSCD
AGOMAB THERAPEUTICS NV - RADIOLOGICAL ASSESSMENT SHOWS TREND FOR FIBROTIC STRICTURE STABILIZATION DURING TREATMENT
Source text: ID:nGNX2x8v9C
Further company coverage: AGMB.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Agomab Therapeutics NV
See all newsBrief: Agomab Announces First Patient Dosed In Global Nov-Era Phase 2B Study Of Ontunisertib In Fibrostenosing Crohn's Disease
Brief: Agomab Reports Positive Topline Data From Stenova Open-Label Extension Study Of Ontunisertib In Fibrostenosing Crohn's Disease
Brief: Agomab Announces Appointments Of Marino Garcia And Dr Naimish Patel To Board Of Directors
Brief: Agomab Announces Proposed Appointments Of Marino Garcia And Dr. Naimish Patel To Board Of Directors
NASDAQ RESUMED AT 04:00 PM